References
- Expert Panel Report 3 (EPR3). Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, US Department of Health and Human Services; 2007 7/2007.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Bethesda, MD: National Heart, Lung, and Blood Institute; 2016.
- Urbano FL. Review of the NAEPP 2007 Expert Panel Report (EPR-3) on asthma diagnosis and treatment guidelines. J Manag Care Pharm. 2008;14(1):41–9.
- Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836–44.
- Flovent Diskus [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014 5/2014.
- Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax. 2005;60(9):730–4.
- Ducharme FM, Ni Chróinín M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010(5):CD005535.
- Advair Diskus [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2014 July 2014.
- Price DB, Pearce L, Powell SR, Shirley J, Sayers MK. Handling and acceptability of the Easi-Breathe device compared with a conventional metered dose inhaler by patients and practice nurses. Int J Clin Pract. 1999;53(1):31–6.
- Virchow JC, Crompton GK, Dal Negro R, Pedersen S, Magnan A, Seidenberg J, et al. Importance of inhaler devices in the management of airway disease. Respir Med. 2008;102(1):10–9.
- O'Conor R, Wolf MS, Smith SG, Martynenko M, Vicencio DP, Sano M, et al. Health literacy, cognitive function, proper use and adherence to inhaled asthma controller medications among older adults with asthma. Chest. 2015;147(5):1307–15.
- Giraud V, Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur Respir J. 2002;19(2):246–51.
- Given J, Taveras H, Iverson H. Prospective, open-label evaluation of a new albuterol multidose dry powder inhaler with integrated dose counter. Allergy Asthma Proc. 2016;37(3):199–206.
- Vutikullird AB, Gillespie M, Song S, Steinfeld J. Pharmacokinetics, safety, and tolerability of a new fluticasone propionate multidose dry powder inhaler compared with fluticasone propionate diskus® in healthy adults. J Aerosol Med Pulm Drug Deliv. 2016;29(2):207–14.
- Miller DS, Yiu G, Hellriegel ET, Steinfeld J. Dose-ranging study of salmeterol using a novel fluticasone propionate/salmeterol multidose dry powder inhaler in patients with persistent asthma. Allergy Asthma Proc. 2016;37(4):291–301.
- Kerwin EM, Gillespie M, Song S, Steinfeld J. Randomized, dose-ranging study of a fluticasone propionate multidose dry powder inhaler in adolescents and adults with uncontrolled asthma not previously treated with inhaled cortico-steroids. J Asthma. 2017;54(1):89–98.
- The Third National Health and Nutrition Examination Survey (NHANES III). 1988–1994 Series 11, no. 9A Data Release. Atlanta, GA: Centers for Disease Control and Prevention; 2001. Available from: https://wwwn.cdc.gov/nchs/data/nhanes3/9a/Readme.txt.
- Bernstein DI, Gillespie M, Song S, Steinfeld J. Safety, efficacy, and dose response of fluticasone propionate delivered via the novel MDPI in patients with severe asthma: a randomized, controlled, dose-ranging study. J Asthma. 2017;54(6):559–69.
- Falcoz C, Oliver R, McDowall JE, Ventresca P, Bye A, Daley-Yates PT. Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet. 2000;39 Suppl 1:9–15.
- Bye A. The oral systemic availability of fluticasone propionate in man–preliminary data. Br J Clin Pharmacol. 1993;36(2):136–7.
- Levy ML, Hardwell A, McKnight E, Holmes J. Asthma patients' inability to use a pressurised metered-dose inhaler (pMDI) correctly correlates with poor asthma control as defined by the Global Initiative for Asthma (GINA) strategy: a retrospective analysis. Prim Care Respir J. 2013;22(4):406–11.